Vyne Therapeutics Inc (VYNE) Annual Income Statement (USD)
VYNE Quarterly Financials (USD)
Frequently Asked Questions About Vyne Therapeutics Inc (VYNE) Stock
Vyne Therapeutics Inc's (VYNE) last reported annual revenue was USD 501000.00.
Vyne Therapeutics Inc's (VYNE) annual revenue growth rate based on the revenue reported in the past 5 years is : -22.13%
Vyne Therapeutics Inc's(VYNE) is not profitable as of its last reported annual financials.
The net profit margin for Vyne Therapeutics Inc's(VYNE) from its laster reported year is -7950.90%
The return on equity (ROE) for Vyne Therapeutics Inc's(VYNE) from its last reported annual financials is : -56.54%
The return on assets (ROA) for Vyne Therapeutics Inc's(VYNE) from its last reported annual financials is : -33.14%
The return on invested capital (ROIC) for Vyne Therapeutics Inc's(VYNE) from its last reported annual financials is : -61.98%
The Debt to Equity ratio for Vyne Therapeutics Inc's(VYNE) from its last reported annual financials is : 0.00%
The dividend yield for Vyne Therapeutics Inc's(VYNE) from its laster reported year is 0.00%
Vyne Therapeutics Inc's(VYNE) has negative cash flow as of its last reported annual financials.
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for VYNE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
